The company maintains a portfolio of clinical programs across a range of neuromuscular, central nervous system, cardiovascular, and metabolic disease indications with a clinical-stage pipeline that includes investigational therapeutics for congestive heart failure, limb-girdle muscular dystrophy, multiple system atrophy, Parkinson's disease, and Pompe disease. Perform a broad range of experimental techniques independently (e.g., cell culture, nucleic acid and protein extraction, qPCR/RT-qPCR/ddPCR, ELISA, SDS-PAGE, Western blot/Jess, and related assays) to support platform and therapeutic programs.